Corporate Governance Statement

This Corporate Governance Statement is current as at 27 June 2026.

In September 2020, Imunexus Therapeutics Limited (**Imunexus**) was incorporated and registered as a public company. As part of its preparations to submit an application for admission to the Official List of the Australian Securities Exchange (**ASX**), in 2026, Imunexus refreshed its Board of Directors, expanded its executive team and enhanced its governance framework. Imunexus' Board is committed to continuing this work and bringing Imunexus' governance practices into alignment with each of the recommendations set by the ASX Corporate Governance Council in the 4th edition of its Corporate Governance Principles and Recommendations (**Recommendations**).

This Corporate Governance Statement discloses the extent to which Imunexus will, as at the date it is admitted to the official list of the ASX, follow the Recommendations. The Recommendations that will not be followed have been identified and reasons for not following them have been provided.

All Charters and Policies referenced in this Statement are available on Imunexus' website.

RECOMMENDATION		COMMENT
PRINCIPLE 1 - LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT		
1.1	A listed entity should have and disclose a board charter setting out: (a) the respective roles and responsibilities of its board and management; and (b) those matters expressly reserved to the board and those delegated to management.	The Board has adopted a written Board Charter which sets out those matters expressly reserved to the Board and those delegated to management. The Board Charter is available on Imunexus' website. The Board is responsible for the overall operation and stewardship of Imunexus. The Board's objectives are to advance Imunexus' strategic direction in all of its day-to-day activities in a way that: (a) provides clear accountability; (b) protects the rights and interests of shareholders and other stakeholders; (c) provides for proper management of Imunexus' assets; (d) supports the achievement of Imunexus' fiduciary, environmental, health, safety, social and other obligations; (e) preserves and enhances Imunexus' reputation and standing in the community; and

		(f) supports the achievement of shareholder value within a framework of appropriate risk assessment and management. In general, the Board is responsible for, and has the authority to determine, all matters relating to Imunexus' planning, policies and practices. The Board is responsible for Imunexus' overall corporate governance and successful operation. It establishes goals for management and ensures that Imunexus is managed in a manner consistent with the agreed objectives. The Board Charter includes an allocation of responsibilities to Board, the Chair, individual Directors, any Managing Director (or equivalent CEO) and the Company Secretary.
1.2	A listed entity should: (a) undertake appropriate checks before appointing a director or senior executive or putting someone forward for election as a director; and (b) provide security holders with all material information in its possession relevant to a decision on whether or not to elect or re-elect a director.	As part of Imunexus' application for admission to the Official List of ASX, each Director (including each proposed Director upon ASX listing) provided to Imunexus a national criminal history check obtained from the Australian Federal Police and a search of the Australian National Personal Insolvency Index. There were no Directors (nor proposed Directors) who had in the past 10 years been a resident of a country other than Australia. Each Director (including each proposed Director upon ASX listing) of Imunexus also made, and provided to Imunexus and ASX, a statutory declaration which included confirmation that the Director (or proposed Director) had not been the subject of any criminal or civil penalty proceedings or other enforcement action by any government agency in which they were found to have engaged in behaviour involving fraud, dishonesty, misrepresentation, concealment of material facts or breach of duty. Imunexus' Prospectus disclosed all material information in Imunexus' possession relating to each Director (and proposed Director upon ASX listing). In Imunexus' Board Charter, the Board commits to undertaking appropriate checks including character, experience, education, criminal record and bankruptcy history to determine whether or not to recommend a Director to shareholders for election or re-election or to appoint a Director to fill a casual vacancy. The Charter also confirms the Board's commitment to providing shareholders with all material information in Imunexus' possession relevant to a decision on whether or not to elect or re-elect a Director. Under its Charter, the Board's Nomination and Remuneration Committee (see Recommendation 2.1 below), has responsibility for ensuring that appropriate checks are undertaken before nominating an individual as a candidate for appointment to the Board.

		Imunexus will ensure that prior to appointing a senior executive, appropriate checks are undertaken.
1.3	A listed entity should have a written agreement with each director and senior executive setting out the terms of their appointment.	Imunexus has a written agreement with each Director (including each proposed Director upon ASX listing) and a written agreement with, or in connection with the services of, each senior executive setting out the terms of their appointment. Each Executive Director and senior executive of Imunexus has a written employment contract with Imunexus setting out the terms of their employment or there is an executive services or consulting agreement outlining the terms of their services. The Board's Nomination and Remuneration Committee is responsible for overseeing the process of appointment and remuneration of Non-Executive Directors, any Managing Director (or equivalent CEO), the CFO (or equivalent), and other senior executives of Imunexus.
1.4	The company secretary of a listed entity should be accountable directly to the board, through the chair, on all matters to do with the proper functioning of the board.	Imunexus' Board Charter provides that the Board has reserved to itself the appointment, and removal, of the Company Secretary and the determination of their remuneration and conditions of service, including any financial incentives. The Board Charter also provides that the Company Secretary is responsible for developing and maintaining the information systems and processes required such that the Board can fulfil its role and is directly accountable to the Board, through the Chair, on all matters relating to the proper functioning of the Board. The Board's Nomination and Remuneration Committee is responsible for overseeing the process of appointment and remuneration of the Company Secretary.
1.5	A listed entity should: (a) have and disclose a diversity policy; (b) through its board or a committee of the board set measurable objectives for achieving gender diversity in the composition of its board, senior executives and workforce generally; and (c) disclose in relation to each reporting period:	Imunexus has adopted a Diversity Policy which sets out Imunexus' commitment to diversity, encouraging inclusive workplace practices and behaviours and fostering a work environment that values the contributions of employees with diverse backgrounds, experiences and perspectives through improved awareness of the benefits of workforce diversity and successful management of diversity. Imunexus' Board Charter provides that the composition of the Board must demonstrate an appropriate mix of skills, experience, diversity and knowledge to discharge its responsibilities and objectives. The responsibilities of the Board's Nomination and Remuneration Committee include:

	(i) the measurable objectives set for that period for to achieve gender diversity; (ii) the entity's progress towards achieving those objectives; and (iii) either: (A) the respective proportions of men and women on the board, in senior executive positions and across the whole organisation (including how the entity has defined "senior executive" for these purposes); or (B) if the entity is a "relevant employer" under the Workplace Gender Equality Act, the entity's most recent "Gender Equality Indicators", as defined in and published under that Act.	(a) identifying and evaluating the necessary and desirable skills, experience and diversity of the Board and Board Committees; (b) developing criteria for the selection of candidates for the Board in the context of the Board's existing composition and structure in light of its desired mix of skills, experience and diversity; (c) identifying any deficiencies in the composition of the Board in light of its collective desired mix of skills, experience and diversity; (d) making recommendations to the Board on the appointment, re-election and removal of Directors in light of the Board's current skills, experience and diversity; and (e) developing a succession plan for the Board with a view to maintaining an appropriate balance of skills, experience and diversity. The Board is responsible for developing measurable objectives and strategies to meet the objectives of the Diversity Policy and to ensure that the Policy aligns with Imunexus' values including measurable objectives (such as numerical targets) for achieving gender diversity in the composition of the Board, Senior Executives and the workforce generally (Measurable Objectives). It is also responsible for reviewing annually both the Measurable Objectives and Imunexus' progress in achieving the Measurable Objectives, through the monitoring, evaluation and reporting mechanisms listed below. In accordance with Recommendation 1.5, Imunexus will report each year on the diversity objectives set by Imunexus and progress towards achieving them and on the respective proportions of men and women on the board, in senior executive positions and across the whole organisation.
1.6	A listed entity should: (a) have and disclose a process for periodically evaluating the performance of the board, its committees and individual directors; and (b) disclose, in relation to each reporting period, whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.	Imunexus' Board Charter provides that an assessment and review of the performance of the Board, its Committees and individual Directors will be undertaken at least annually. Imunexus' Nomination and Remuneration Committee is responsible for reviewing and making recommendations to the Board in respect of the development and implementation of a process for evaluating the performance of the Board, Board committees and individual Directors. In accordance with Recommendation 1.6, Imunexus will disclose the process adopted for evaluating the performance of the Board, its Committees and individual Directors and

		disclose in relation to each reporting period, whether or not a performance evaluation was undertaken in the reporting period in accordance with that process.
1.7	A listed entity should: (a) have and disclose a process for evaluating the performance of its senior executives at least once every reporting period; and (b) disclose for each reporting period, whether a performance evaluation has been undertaken in accordance with that process during or in respect of that period.	The Charter of Imunexus' Nomination and Remuneration Committee provides that the Committee is responsible for developing criteria for evaluation and making recommendations to the Board regarding performance management policies and procedures for Executive Directors and direct reports to the Managing Director (or equivalent CEO). The Committee is also responsible for developing and reviewing remuneration practices and policies. Imunexus is committed to aligning its performance evaluation processes in respect of all senior executives with this recommendation. In accordance with Recommendation 1.7, Imunexus will disclose for each reporting period the process adopted for periodically evaluating the performance of Imunexus' senior executives and whether or not a performance evaluation was undertaken in the reporting period in accordance with that process.
PRINCIPLE 2 - STRUCTURE THE BOARD TO BE EFFECTIVE AND ADD VALUE		
2.1	The board of a listed entity should: (a) have a nomination committee which: (i) has at least three members, a majority of whom are independent directors; and (ii) is chaired by an independent director, and disclose: (iii) the charter of the committee; (iv) the members of the committee; and (v) as at the end of each reporting period, the number of times the committee met throughout the period and the individual	The Board has established a Nomination and Remuneration Committee. As at the date of Imunexus' application for admission to the ASX, the composition of the Nomination and Remuneration Committee does not meet the Recommendation that it have at least three members and comprise a majority of independent directors as it only has two members, Philippa Lewis and Donald Brumley, with only Mr Brumley considered to be independent. However, proposed director Robert McInnes is considered to be independent and his appointment to the Board and the Nomination and Remuneration Committee as Chair of the Committee after the Company's successful admission to the ASX will provide the Nomination and Remuneration Committee with three members, a majority of whom are independent directors and an independent Committee Chair. Notwithstanding these departures at the date of this Imunexus' application for admission to ASX, the Board considers that the proposed composition of the Nomination and Remuneration Committee after its successful Admission will comply with the Recommendation.

	attendances of the members at those meetings; or (b) if it does not have a nomination committee, disclose that fact and the processes it employs to address board succession issues and to ensure that the board has the appropriate balance of skills, knowledge, experience, independence and diversity to enable it to discharge its duties and responsibilities effectively.	The Charter of the Nomination and Remuneration Committee is available on Imunexus' website. Imunexus has disclosed the proposed members of the Nomination and Remuneration Committee in its Prospectus. Imunexus will disclose as at the end of each reporting period, in its annual report, the members of the Committee and the number of times the Committee met throughout the reporting period and the individual attendances of the members of the Committee at those meetings.
2.2	A listed entity should have and disclose a board skills matrix setting out the mix of skills and diversity that the board currently has or is looking to achieve in its membership.	Imunexus does not yet have a formal skills matrix setting out the mix of skills and diversity that the Board seeks to achieve in its membership. It intends to develop its skills matrix and disclose details of the Board's skills matrix in its annual corporate governance statement. The responsibilities of the Nomination and Remuneration Committee include: (a) develop criteria for the selection of candidates for the Board in the context of the Board's existing composition and structure in light of its desired mix of skills, experience and diversity; (b) identify any deficiencies in the composition of the Board in light of its collective desired mix of skills, experience and diversity and whether such deficiencies should be addressed by further professional development or the appointment or removal of a Director; (c) make recommendations to the Board on the appointment, re-election and removal of Directors in light of the Board's current skills, experience and diversity; and (d) develop a succession plan for the Board with a view to maintaining an appropriate balance of skills, experience and diversity.
2.3	A listed entity should disclose: (a) the names of the directors considered by the board to be independent directors; (b) if a director has an interest, position, or relationship of the type described in Box 2.3	Imunexus expects its Board to comprise five Directors: (a) Philippa Lewis, Chair and CEO; (b) Donald Brumley; (c) Christopher Elliot, CFO;

	but the board is of the opinion that it does not compromise the independence of the director, the nature of the interest, position, or relationship in question and an explanation of why the board is of that opinion; and (c) the length of service of each director.	(d) Dr David Fuller (proposed); and (e) Robert McInnes (proposed). Imunexus' Board Charter provides that as a general principle, independent Directors are those who are free of any interest, position or relationship that might influence, or reasonably be perceived to influence, in a material respect their capacity to bring an independent judgement on issues before the Board and to act in the best interests of Imunexus as a whole rather than the interests of an individual shareholder or third party. The Charter provides that the approach and attitude of a non-executive Director is a critical factor in determining his or her independence and the factors relevant to assessing the independence of a non-executive Director include if the Director: (a) is not or does not represent a substantial shareholder of the Company or has not, within the last three years, been an Officer of, an employee of, or professional advisor to a substantial shareholder of the Company (as defined in section 9 of the Corporations Act); (b) has not, within the last three years, been employed in an executive capacity by the Company or another Group member, or been a Director after ceasing to hold any such employment; (c) receives performance-based remuneration (including options or performance rights) or participates in an employee incentive scheme of the Company; (d) is not, or has not within the last three years been, a material supplier, professional adviser, consultant or customer of the Company or other Group member, or an Officer of or otherwise associated, directly or indirectly, with a material supplier, professional adviser, consultant or customer; (e) has close personal ties with any person who falls within the categories described above; (f) has not served on the Board for a period in the past which could, or could reasonably be perceived to, compromise the Director's independence or materially interfere with the Director's ability to act in the current best interests of the Company; and

		(g) is free from any interest and any business, familial, friendship, social other relationship which could, or could reasonably be perceived to, materially interfere with the Director's ability to act in the best interests of the Company. Imunexus has disclosed, in the Prospectus the Directors considered by the Board to be independent. Following admission to the ASX, three members of Imunexus' Board are considered by the Board to be independent, being Donald Brumley, Dr David Fuller (proposed Director) and Robert McInnes (proposed Director). Imunexus' Nomination and Remuneration Committee is responsible for assessing at least annually, or more frequently if a Director's material interests or affiliations have changed, the independence of individual Directors and making recommendations to the Board as to whether or not a Director's status as an independent Director has changed. Imunexus' Board Charter provides that each Non-Executive Director must provide to the Board all information relevant to the assessment of his or her independence and must disclose to the Board any actual, perceived or potential conflicts of interest or duty, or matter that may bear on their independence and might reasonably be thought to exist as soon as the situation arises. If a Director's independent status changes, this will be immediately disclosed and explained in an announcement to ASX.
2.4	A majority of the board of a listed entity should be independent directors.	At the date of this Imunexus' application for admission to ASX, the Board does not comply with the Recommendation as only one of the Company's three Directors, Donald Brumley, is considered to be independent. However, proposed directors Dr David Fuller and Robert McInnes are both considered to be independent and their appointment to the Board after the successful admission to ASX will provide the Company with a majority of independent directors on the Board. Notwithstanding the departure at the date of Imunexus' application for admission to ASX, the Board considers that the proposed composition of the Board after its successful admission to ASX will comply with the Recommendation. The Company will continue to assess the independence of each Director and will consider this Recommendation in connection with each future Board appointment.

2.5	The chair of the board of a listed entity should be an independent director and, in particular, should not be the same person as the CEO of the entity.	Imunexus does not currently follow this Recommendation. Philippa Lewis is the Executive Chair of the Board and is therefore not considered by the Board to be an independent Director. The Board considers that Philippa Lewis is an appropriate Chair at this stage of Imunexus' development, having regard to her knowledge of Imunexus' business, strategy, operations and industry.
2.6	A listed entity should have a program for inducting new directors and periodically reviewing whether there is a need for existing directors to undertake professional development to maintain the skills and knowledge needed to perform their role as directors effectively.	Imunexus' induction program for the current Directors include operational site visits, meetings with members of the executive management team, and provision of corporate and financial management information regarding the Company and governance-related material. Imunexus will maintain an induction program for new Directors to assist them in becoming familiar with the Company, its executives, its business, and its regulatory environment. Imunexus will have an induction program for new directors to assist them in becoming familiar with the Company, its executives, its business and its regulatory environment. Imunexus' Nomination and Remuneration Committee is responsible for developing and implementing induction programs for Directors and making recommendations to the Board in respect of an effective induction program for new Directors and a professional development program for Directors.
PRINCIPLE 3 – INSTIL A CULTURE OF ACTING LAWFULLY, ETHICALLY AND RESPONSIBLY		
3.1	A listed entity should articulate and disclose its values	Imunexus has articulated its values in its Code of Conduct. Imunexus' core values are scientific excellence, patient impact, integrity and transparency, and value creation. The Code of Conduct is available on Imunexus' website.
3.2	A listed entity should: (a) have and disclose a code of conduct for its directors, senior executives and employees; and (b) ensure that the board or a committee of the board is informed of any material breaches of that code.	Imunexus is committed to making positive economic, social and environmental contributions to each of the communities in which it operates, while complying with all applicable laws and regulations and acting in a manner that is consistent with its foundational principles of honesty, integrity, fairness and respect. Imunexus has adopted a Code of Conduct whose purpose is to provide a framework for decisions and actions in relation to conduct in respect of employment. It underpins Imunexus' commitment to provide professional services and its duty of care to all

		employees, stakeholders and clients receiving those services. It should be read in conjunction with Imunexus' Diversity Policy. Staff members are expected to act consistently with the fundamental principles set out in the Code at all times. Similarly, the Code informs consultants, contractors and partners working with or for Imunexus of these principles, the Company's expectations and their obligation to act in accordance with them. The Code of Conduct provides that material non-compliance with the Code will be reported to the full Board immediately.
3.3	A listed entity should: (a) have and disclose a whistleblower policy; and (b) ensure that the board or a committee of the board is informed of any material incidents reported under that policy.	In recognition of the important role whistleblowing can play in the early detection of misconduct and the fact that individuals who are considering disclosing misconduct may fear retribution or other detriment and require an assurance of protection, Imunexus has adopted a Whistleblower Policy. Imunexus' Whistleblower Policy encourages employees to report actual or suspected misconduct, wrongdoing or an improper state of affairs or circumstances. The Whistleblower Policy establishes mechanisms and procedures for receiving, handling and investigating disclosures, protecting whistleblowers and supporting the investigation of reports. A copy of Imunexus' Whistleblower Policy is available on Imunexus' website. The Whistleblower Policy provides that whistleblower notices will be reported to the Audit and Risk Committee at each meeting and between meetings, as necessary.
3.4	A listed entity should: (a) have and disclose an anti-bribery and corruption policy; and (b) ensure that the board or a committee of the board is informed of any material breaches of that policy.	Imunexus has an Anti-Bribery and Corruption Policy for Directors, employees, contractors, volunteers, agents and directors of Imunexus. The Policy prohibits bribery, facilitation payments, kickbacks, extortion and secret commissions, and establishes requirements in relation to gifts and hospitality, foreign public officials, intermediaries, agents and business partners. The Policy prohibits facilitation payments, kickbacks and donations to political parties or which are intended to obtain an improper advantage for Imunexus. A copy of the Policy is available on Imunexus' website. The Anti Bribery and Corruption Policy provides that reporting and accountability with respect to the terms of the Policy will be a periodic item on the Board's agenda.

PRINCIPLE 4 – SAFEGUARD INTEGRITY IN CORPORATE REPORTING		
4.1	The board of a listed entity should: (a) have an audit committee which: (i) has at least three members, all of whom are non-executive directors and a majority of whom are independent directors; and (ii) is chaired by an independent director, who is not the chair of the board, and disclose: (iii) the charter of the committee; (iv) the relevant qualifications and experience of the members of the committee; and (v) in relation to each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have an audit committee, disclose that fact and the processes it employs that independently verify and safeguard the integrity of its corporate reporting, including the processes for the appointment and removal of the external auditor and the rotation of the audit engagement partner.	The Board has established an Audit and Risk Committee (**ARC**). As at the date of Imunexus' application for admission to ASX, the composition of the Audit and Risk Committee does not meet the Recommendation that it have at least three members and comprise a majority of independent non-executive directors as it only has two members, Philippa Lewis and Donald Brumley, with only Mr Brumley, who serves as the Committee Chair, considered to be independent. However, proposed director Dr David Fuller is considered to be independent and his appointment to the Board and the Audit and Risk Committee after the successful Admission of the Company will provide the Committee with three members, a majority of whom are independent non-executive directors. Notwithstanding these departures at the date of Imunexus' application for admission to ASX, the Board considers that the proposed composition of the Audit and Risk Committee after its successful admission to ASX will comply with the Recommendation. The members of the ARC and their relevant qualifications and experience are disclosed, or will be disclosed, in Section 5 the Prospectus. The Charter of the ARC is available on Imunexus' website. Imunexus will disclose in relation to each reporting period, in its annual report, the relevant qualifications and experience of the members of the ARC, the number of times the ARC met throughout the reporting period and the individual attendances of the members of the ARC at those meetings.
4.2	The board of a listed entity should, before it approves the entity's financial statements for a	Imunexus will comply with this Recommendation. The Board Charter provides that, before the Directors' declaration in the Company's financial statements is made, the CFO or

	financial period, receive from its CEO and CFO a declaration that, in their opinion, the financial records of the entity have been properly maintained and that the financial statements comply with the appropriate accounting standards and give a true and fair view of the financial position and performance of the entity and that the opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.	equivalent and the person performing a chief executive function within the Company must provide the Board with the declarations required by section 295A of the Corporations Act. The Board Charter also provides that, in accordance with Recommendation 4.2, the Board must receive assurances that the declaration is founded on a sound system of risk management and internal control and that the system is operating effectively in all material respects in relation to financial reporting.
4.3	A listed entity should disclose its process to verify the integrity of any periodic corporate report it releases to the market that is not audited or reviewed by an external auditor.	Imunexus will comply with this Recommendation. The Board, with the assistance of the Audit and Risk Committee, will oversee the process for verifying the integrity of any periodic corporate report released to the market that is not audited or reviewed by an external auditor. This process may include review by management, review by the CFO or equivalent, review by relevant subject matter experts and, where appropriate, review by the Board or the Audit and Risk Committee before release.
PRINCIPLE 5 – MAKE TIMELY AND BALANCED DISCLOSURE		
5.1	A listed entity should have and disclose a written policy for complying with its continuous disclosure obligations under listing rule 3.1.	Imunexus has adopted a Continuous Disclosure and Shareholder Communication Policy which sets out the procedures that apply to the central collection, control, assessment and if required, release to the ASX, of information which may affect the price or value of Imunexus securities or influence decisions taken by investors to buy or sell Imunexus securities. Imunexus' Continuous Disclosure and Shareholder Communication Policy is available on Imunexus' website. As a standing agenda item at each Board meeting, Imunexus' Directors will consider whether there is any information (including any matters reported to or discussed at the Board meeting) that may potentially need to be disclosed to the market pursuant to Imunexus' continuous disclosure obligations. The Continuous Disclosure and Shareholder Communication Policy provides that the Secretary is responsible for coordinating disclosure of information to ASX and communicating with ASX. It also provides that all material market announcements are to be

		reviewed and approved before release in accordance with the procedure set out in the Policy.
5.2	A listed entity should ensure that its board receives copies of all material market announcements promptly after they have been made.	Imunexus will comply with this Recommendation. The Continuous Disclosure and Shareholder Communication Policy provides that, after confirmation of release has been obtained from ASX, the Secretary will circulate each release to all Directors and officers of the Company.
5.3	A listed entity that gives a new substantial investor or analyst presentation should release a copy of the presentation materials on the ASX Market Announcements Platform ahead of the presentation.	Imunexus will comply with this Recommendation. The Continuous Disclosure and Shareholder Communication Policy provides that any new and substantive investor or analyst presentation will be released to ASX on the ASX Market Announcements Platform ahead of the presentation.
PRINCIPLE 5 – RESPECT THE RIGHTS OF SECURITY HOLDERS		
6.1	A listed entity should provide information about itself and its governance to investors via its website.	Imunexus' website provides ready access to information about the Company, the Board, the senior management team, Imunexus' governance practices and Imunexus' products. Upon listing, Imunexus will have an investor section of its website providing information about Imunexus' share price performance and ready access to ASX announcements including financial reports and investor presentations. Shareholders and other interested parties will be able to subscribe, via the Investor page on Imunexus' website, to receive email alerts regarding the release of Imunexus ASX announcements.
6.2	A listed entity should have an investor relations programme that facilitates effective two-way communication with investors.	Imunexus has a Continuous Disclosure and Shareholder Communication Policy setting out the Company's shareholder communication processes. The Policy is available on Imunexus' website. Investors are able to contact Imunexus or submit questions or comments to Imunexus via the 'Contact us' page on Imunexus' website, and where appropriate, a response is provided.

6.3	A listed entity should disclose how it facilitates and encourages participation at meetings of security holders.	Imunexus will facilitate and encourage participation at meetings of security holders by offering shareholders the following: (a) attendance at shareholder meetings in person; (b) lodgement of votes online via its share registry's electronic meeting technology systems; and (c) the opportunity to appoint a proxy to attend the meeting and vote on their behalf. The Continuous Disclosure and Shareholder Communications Policy also provides that shareholders will have a reasonable opportunity to ask questions of the Board and otherwise participate in general meetings.
6.4	A listed entity should ensure that all substantive resolutions at a meeting of security holders are decided by a poll rather than by a show of hands.	Imunexus is committed to complying with this Recommendation. The Continuous Disclosure and Shareholder Communications Policy provides that all substantive resolutions at general meetings will be conducted by a poll.
6.5	A listed entity should give security holders the option to receive communications from, and send communications to, the entity and its security registry electronically.	Security holders will have the option to receive communications from, and send communications to Imunexus and its share registry, Boardroom, electronically. Imunexus will actively encourage shareholders to receive communications electronically, by including an electronic communications preference form in its new shareholder welcome pack and in mailing packs for shareholder meetings. Imunexus' share registry, Boardroom, also receives and sends electronic communications to shareholders.
PRINCIPLE 6 – RECOGNISE AND MANAGE RISK		
7.1	The board of a listed entity should: (a) have a committee or committees to oversee risk, each of which: (i) has at least three members, a majority of whom are independent directors; and	The Board has established an Audit and Risk Committee (ARC). As at the date of Imunexus' application for admission to ASX, the composition of the Audit and Risk Committee does not meet the Recommendation that it have at least three members and comprise a majority of independent non-executive directors as it only has two members, Philippa Lewis and Donald Brumley, with only Mr Brumley, who serves as the Committee Chair, considered to be independent. However, proposed director Dr David Fuller is considered to be independent and his appointment to the Board and the Audit and Risk

	(ii) is chaired by an independent director, and disclose: (iii) the charter of the committee; (iv) the members of the committee; and (v) as at the end of each reporting period, the number of times the committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a risk committee or committees that satisfy (a) above, disclose that fact and the processes it employs for overseeing the entity's risk management framework.	Committee after the successful Admission of the Company will provide the Committee with three members, a majority of whom are independent non-executive directors. Notwithstanding these departures at the date of Imunexus' application for admission to ASX, the Board considers that the proposed composition of the Audit and Risk Committee after its successful admission to ASX will comply with the Recommendation. Imunexus will disclose in relation to each reporting period, in its annual report, the number of times the ARC met throughout the reporting period and the individual attendances of the members of the ARC at those meetings.
7.2	The board or a committee of the board should: (a) review the entity's risk management framework at least annually to satisfy itself that it continues to be sound and that the entity is operating with due regard to the risk appetite set by the board; and (b) disclose, in relation to each reporting period, whether such a review has taken place.	The Board is responsible for considering, approving and monitoring the Group's systems of risk management, accountability, compliance and control. The Board has delegated to the ARC responsibility for: (a) overseeing the establishment and maintenance by management of processes to ensure that there is an adequate and effective system to identify and manage material business risks; and (b) monitoring and evaluating the adequacy of the Company's risk management procedures by receiving reports from management and the external auditor. The Board, with the assistance of the ARC, will review the Company's risk management framework at least annually to satisfy itself that it continues to be sound. The ARC will also review the risk appetite statement set by the Board at least annually.
7.3	A listed entity should disclose:	Given its size, the Company does not currently have a separate internal audit function.

	(a) if it has an internal audit function, how the function is structured and what role it performs; or (b) if it does not have an internal audit function, that fact and the processes it employs for evaluating and continually improving the effectiveness of its governance, risk management and internal control processes.	The Board has delegated to the ARC responsibility for monitoring and evaluating the adequacy of the Company's risk management procedures by receiving reports from management and the external auditor. Details of the processes the Company has employed during a reporting period for evaluating and continually improving the effectiveness of the Company's risk management and internal control processes will be disclosed in the Company's Annual Corporate Governance Statement.
7.4	A listed entity should disclose whether it has any material exposure to environmental or social risks and if it does, how it manages or intends to manage those risks.	Imunexus has detailed the key risks to which it is exposed in Section 3 of the Prospectus. Imunexus has also adopted an ESG Policy which provides a framework for identifying, assessing, monitoring and reporting material environmental, social and governance risks. Imunexus will continue to review and refine the ESG Policy as part of its broader governance framework. Imunexus will disclose in its annual Corporate Governance Statement whether it has any material exposure to environmental or social risks and, if it does, how it manages or intends to manage those risks.
PRINCIPLE 7 – REMUNERATE FAIRLY AND RESPONSIBLY		
8.1	The board of a listed entity should: (a) have a remuneration committee which: (i) has at least three members, a majority of whom are independent directors; and (ii) is chaired by an independent director, and disclose: (iii) the charter of the committee; (iv) the members of the committee; and (v) as at the end of each reporting period, the number of times the	The Board has established a Nomination and Remuneration Committee. As at the date of Imunexus' application for admission to the ASX, the composition of the Nomination and Remuneration Committee does not meet the Recommendation that it have at least three members and comprise a majority of independent directors as it only has two members, Philippa Lewis and Donald Brumley, with only Mr Brumley considered to be independent. However, proposed director Robert McInnes is considered to be independent and his appointment to the Board and the Nomination and Remuneration Committee as Chair of the Committee after the Company's successful admission to the ASX will provide the Nomination and Remuneration Committee with three members, a majority of whom are independent directors and an independent Committee Chair. Notwithstanding these departures at the date of this Imunexus' application for admission to ASX, the Board considers that the proposed composition of the Nomination and Remuneration Committee after its successful Admission will comply with the Recommendation.

	committee met throughout the period and the individual attendances of the members at those meetings; or (b) if it does not have a remuneration committee, disclose that fact and the processes it employs for setting the level and composition of remuneration for directors and senior executives and ensuring that such remuneration is appropriate and not excessive.	The overriding objective of the Committee is to provide an independent and objective perspective on the value and structure of remuneration for Imunexus' Non-executive Directors, Managing Director (or equivalent CEO), CFO (or equivalent), and other senior executives and employees, so as to maximise the benefit derived from their skills and experience and facilitate Imunexus' long-term growth and success. The Charter of the Nomination and Remuneration Committee is available on Imunexus' website. Imunexus will disclose as at the end of each reporting period, in its annual report, the members of the Committee and the number of times the Committee met throughout the reporting period and the individual attendances of the members of the Committee at those meetings.
8.2	A listed entity should separately disclose its policies and practices regarding the remuneration of non-executive directors and the remuneration of executive directors and other senior executives.	Imunexus disclosed in its Prospectus its policies and practices regarding the remuneration of Non-Executive Directors and the remuneration of the Executive Chair and CEO and other senior executives. Please refer to Section 5 of the Prospectus. Imunexus will disclose as at the end of each reporting period, in its annual report, its policies and practices regarding the remuneration of Non-Executive Directors and the remuneration of the Managing Director and other senior executives.
8.3	A listed entity which has an equity-based remuneration scheme should: (a) have a policy on whether participants are permitted to enter into transactions (whether through the use of derivatives or otherwise) which limit the economic risk of participating in the scheme; and (b) disclose that policy or a summary of it.	Imunexus' Share Trading Policy prohibits Directors and employees from entering into an arrangement that would have the effect of limiting their exposure to risk relating to either unvested remuneration, or vested remuneration which remains subject to a holding lock. A copy of Imunexus' Share Trading Policy will be disclosed on the ASX Market Announcements Platform and is available on Imunexus' website.